Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2016 May 28:19:5-8.
doi: 10.1016/j.rmcr.2016.05.008. eCollection 2016.

Lung histopathological pattern in a survivor with rapidly progressive interstitial lung disease and anti-melanoma differentiation-associated gene 5 antibody-positive clinically amyopathic dermatomyositis

Affiliations
Case Reports

Lung histopathological pattern in a survivor with rapidly progressive interstitial lung disease and anti-melanoma differentiation-associated gene 5 antibody-positive clinically amyopathic dermatomyositis

Atsushi Suzuki et al. Respir Med Case Rep. .

Abstract

Anti-melanoma differentiation-associated gene 5 (MDA5) antibodies are specific indicators of patients with dermatomyositis, particularly clinically amyopathic dermatomyositis (CADM). CADM is occasionally accompanied by fatal, treatment-resistant, rapidly-progressive interstitial lung disease (RP-ILD). All previous reports showed that histopathological findings in RP-ILD with anti-MDA5 antibody-positive CADM indicated diffuse alveolar damage (DAD). This is the first report describing a non-DAD pattern in RP-ILD with anti-MDA5 antibody-positive CADM, which was improved by immunosuppressive therapy. This case may be a milder clinical phenotype than a typical DAD pattern in RP-ILD with anti-MDA5 antibody-positive CADM.

Keywords: 6MWD, six-min walk distance; CADM; CADM, clinically amyopathic dermatomyositis; CT, computed tomography; DAD; DAD, diffuse alveolar damage; DLco, diffusing capacity of the lung for carbon monoxide; FVC, forced vital capacity; IVCY, intravenous cyclophosphamide; Lung histopathological pattern; MDA5; MDA5, melanoma differentiation-associated gene 5; MMRC, modified medical research council dyspnea scale; NSIP, nonspecific interstitial pneumonia; RP-ILD; RP-ILD, rapidly progressive interstitial lung disease.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Physical findings suggestive of clinically amyopathic dermatomyositis. a) facial erythema and heliotrope rash; b) erythema over the V area of the neck; c) scaly erythema with ulceration over the elbow; d) Gottron’s sign.
Fig. 2
Fig. 2
Chest computed tomography. Peribronchovascular ground-glass opacities and bilateral subpleural reticular opacities.
Fig. 3
Fig. 3
Histopathological findings in lung biopsy specimen. a) diffuse involvement in secondary lobule with mild peripheral accentuation [haematoxylin-eosin (HE) stain]; b) accumulation of foamy macrophages accentuated in the periphery of the lobule along with a few neutrophils [HE stain]; c) no hyaline membrane or extensive fibrin are seen, but rare and scant airspace fibrin is found [HE stain]; d) Scattered Masson bodies as organizing pneumonia incorporating surrounding alveolar ducts in less than 20% of area [Elastica van Gieson stain]. Scale bars: 900 μm (a), 200 μm (b, c, d).

References

    1. Koga T., Fujikawa K., Horai Y. The diagnostic utility of anti-melanoma differentiation-associated gene 5 antibody testing for predicting the prognosis of Japanese patients with DM. Rheumatology. 2012;51:1278–1284. - PubMed
    1. Gono T., Kawaguchi Y., Satoh T. Clinical manifestation and prognostic factor in anti-melanoma differentiation-associated gene 5 antibody-associated interstitial lung disease as a complication of dermatomyositis. Rheumatology. 2010;49:1713–1719. - PubMed
    1. Muro Y., Sugiura K., Hoshino K., Akiyama M. Disappearance of anti-MDA-5 autoantibodies in clinically amyopathic DM/interstitial lung disease during disease remission. Rheumatology. 2012;51:800–804. - PubMed
    1. Sato S., Kuwana M., Fujita T., Suzuki Y. Anti-CADM-140/MDA5 autoantibody titer correlates with disease activity and predicts disease outcome in patients with dermatomyositis and rapidly progressive interstitial lung disease. Mod. Rheumatol. 2013;23:496–502. - PubMed
    1. Sontheimer R.D. Would a new name hasten the acceptance of amyopathic dermatomyositis (dermatomyositis sine myositis) as a distinctive subset within the idiopathic inflammatory dermatomyopathies spectrum of clinical illness? J. Am. Acad. Dermatol. 2002;46:626–636. - PubMed

Publication types

LinkOut - more resources